The approval and success of powerful new cancer treatments such as CAR T-cell therapy are breeding optimism among companies, scientists and patients around the world.TD2 can help influence your trial design and get your drug on a faster path to approval.
September 30, 2020
- Advancing Preclinical Research in Gynecologic Cancers
- History of CAR T-cells and Their Continued Use in Hematological Malignancies to Advance Next-Generation Therapies
- Cancer Support: Contract Research Organizations, More Than a Vendor, a Partner In Drug Development.
- Advancing Bone and Sarcoma Cancer Research Through Robust In Vivo Models
- How the FDA’s Plausible Mechanism Framework Signals the Future of Precision Oncology
Advancing Preclinical Research in Gynecologic Cancers
Gynecologic cancers, including endometrial and ovarian cancers, remain areas of high unmet need. Advances in targeted therapy, immunotherapy, ...
History of CAR T-cells and Their Continued Use in Hematological Malignancies to Advance Next-Generation Therapies
CAR T-cell therapy originated in the late 1980s, first-generation constructs lacked adequate co-stimulatory signaling, causing poor CAR T-cell ...
Cancer Support: Contract Research Organizations, More Than a Vendor, a Partner In Drug Development.
Developing cancer therapies is an incredibly complex, costly, and highly regulated journey. To navigate this challenging terrain, pharmaceutical and ...
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
